OOIR: Observatory of International Research

Papers

(The median citation count of Hepatology Communications is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	255
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	181
Issue Information	154
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	97
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	96
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	92
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	92
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	74
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	73
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study	72
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis	60
Pharmacist‐led educational interventions involving the “hidden” patient in cirrhosis—Caregivers	60
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	58
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	58
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	56
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	56
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	55
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	55
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	53
Development and evaluation of a virtual reality driving test for patients with cirrhosis	53
Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	53
Complementary and alternative medicines and liver disease	51
Association between widespread pain and associated symptoms in patients with cirrhosis	49
Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease	47
Visualizing in situ viral replication across the natural history of chronic HBV infection	47

Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	47
Granulomatous liver diseases	44
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	43
A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis	43
Depression and anxiety management in cirrhosis	43
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	42
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	42
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	40
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	40
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	40
Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes	39
COVID‐19 and the Uncovering of Health Care Disparities in the United States, United Kingdom and Canada: Call to Action	39
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	39
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	39
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)	37
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	36
A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis	36
CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway	35
Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?	35
A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers	35
Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver	34
Increased MASH-associated liver cancer in younger demographics	34
CD36 in liver diseases	34
Hepatocyte TGF‐β Signaling Inhibiting WAT Browning to Promote NAFLD and Obesity Is Associated With Let‐7b‐5p	34
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”	34
EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation	34
GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma	34
High prevalence of liver fibrosis among general population: a Romanian population-based study: Erratum	34
SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function	33
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	33
Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy	33
Fatty acid synthesis is indispensable for Kupffer cells to eliminate bacteria in ALD progression	33
Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing	32
Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis	31
HBV core protein enhances WDR46 stabilization to upregulate NUSAP1 and promote HCC progression	31
TGFβ‐induced FOXS1 controls epithelial–mesenchymal transition and predicts a poor prognosis in liver cancer	30
Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age	30
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC	30
Immunoglobulin M: A Neglected Serum Biomarker in Treatment‐Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase	29
Hepatocellular carcinoma cells downregulate NADH:Ubiquinone Oxidoreductase Subunit B3 to maintain reactive oxygen species homeostasis	29
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis	29
Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review	28
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease	28
Alpha-fetoprotein: Past, present, and future	28
Synonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease	28
A need for confirmatory testing of isolated HBcAb-positive results in screening programs	28
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells	27
Intestinal virome in patients with alcohol use disorder and after abstinence	27
Loss of heat shock factor 1 promotes hepatic stellate cell activation and drives liver fibrosis	27
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program	27

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta	27
Cellular communication networks in fibrosis: Insights from the MASLD pig model	26
Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial	26
The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis	26
Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)	26
An Analysis of Free‐Text Refusals as an Indicator of Readiness to Accept Organ Offers in Liver Transplantation	26
Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS	26
Lipid droplet deposition in the regenerating liver: A promoter, inhibitor, or bystander?	26
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites	25
	24
Toll-like receptor 2 activation in monocytes contributes to systemic inflammation and alcohol-associated liver disease in humans	24
Liver Cancer Has a Distinctive Profile in Black Patients: Current Screening Guidelines May Be Inadequate	24
Erratum: Clinical spectrum and genetic causes of mitochondrial hepatopathy phenotype in children	24
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways thro	24
Clinical predictors and noninvasive imaging in Fontan-associated liver disease: A systematic review and meta-analysis	24
Steroid responsiveness in alcohol-associated hepatitis is linked to glucocorticoid metabolism, mitochondrial repair, and heat shock proteins	23
Meaningful differences in patient-reported outcome measurement scores in liver disease	23
Long-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis	23
Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives	23
A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-associated hepatitis	23
Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients	23
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study	23
Falls and malnutrition are associated with in-hospital mortality in patients with cirrhosis	23
Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021	23
The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study	22
Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis	22
Diet composition impacts the natural history of steatotic liver disease	22
Repurposing of the analgesic Neurotropin for MASLD/MASH treatment	21
Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies	21
A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance	21
Current and Emerging Tools for Hepatocellular Carcinoma Surveillance	21
Erratum: Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality	21
CD4+ T-cell subsets in autoimmune hepatitis: A review	21
Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning	21
Hepatology Communications Achieves First Impact Factor and MEDLINE Indexing	21
A strategy for varices screening based on acoustic radiation force impulse combined with platelet (CHESS2001): An alternative of Baveno VI criteria: Erratum	20
Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease	20
Erratum: Use and outcome of transjugular intrahepatic portosystemic shunt in hospitalized patients Germany:Nationwide study (2007-2018)	20
	20
An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD	20
	20
Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment	20
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid	19
Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs	19
Reply: Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?	19
HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening	19
Response to Tinospora cordifolia (Giloy)‐induced liver injury during the COVID‐19 pandemic—Multicenter nationwide study from India	19
Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2−/− mouse model of sclerosing cholangitis via immunomodulatory effects	19
Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction	19
Acute on chronic liver failure: prognostic models and artificial intelligence applications	19
Amphisome plays a role in HBV production and release through the endosomal and autophagic pathways	19
Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease	19
Functional involvement of endothelial lipase in hepatitis B virus infection	19
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis	19
Reply: Antibiotic prophylaxis in palliative patients with cirrhosis: Stewardship or gatekeeping?	19
Aspirin is associated with a reduced incidence of liver disease in men	19
A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction–associated steatotic liver disease	19
Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria	19
	18
Genome‐Wide Association Study of NAFLD Using Electronic Health Records	18
miR-34a regulates macrophage-associated inflammation and angiogenesis in alcohol-induced liver injury	18
	18
Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease: Erratum	18
Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling	18
Growth hormone deficiency and NAFLD: An overlooked and underrecognized link	18
Erratum: Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD)	18
Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors	18
Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis	17
NME2 modulates HCC progression through 4EBP1 phosphorylation and autophagy regulation independent of mTOR	17
Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling	17
Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target	17
Hepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis	17
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha‐Methylacyl‐Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen‐Activated Protein Kinase	17
Erratum: BTLA deficiency promotes HSC activation and protects against hepatic ischemia-reperfusion injury	17
Severe Alcohol‐Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure	17
METTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis	17
Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model	17
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3	17
Gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damage	17
Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review	17

Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7‐year national inpatient sample study	17
WNT7B Regulates Cholangiocyte Proliferation and Function During Murine Cholestasis	17
Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial	16
High‐Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases	16
ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway	16
Population screening for cirrhosis	16
A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis	16
Post-translational modifications drive the effects of HMGB1 in alcohol-associated liver disease	16
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018	16
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models	16
Clinical utility of two-step hepatitis E virus IgM antibody testing in a low-prevalence setting: A 10-year retrospective multicenter study	16
Outcomes of patients with acute liver failure not listed for liver transplantation: A cohort analysis	16
Activin B promotes the initiation and progression of liver fibrosis	16
The most impactful findings on liver cancer in 2023	16
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature	15
Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death	15
	15
Low vitamin A levels are associated with liver-related mortality: a nationally representative cohort study	15
NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6–driven pyroptosis and inflammation	15
Long-term HBV infection of engineered cultures of induced pluripotent stem cell-derived hepatocytes	15
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis	15
Severe acute hepatitis of unknown etiology in a large cohort of children	15
Direct Conversion of Human Endothelial Cells Into Liver Cancer‐Forming Cells Using Nonintegrative Episomal Vectors	15
Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases	15
Bile acid conjugation deficiency causes hypercholanemia, hyperphagia, islet dysfunction, and gut dysbiosis in mice	15
Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC	15
	15
Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease	15
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening	15
Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease	15
Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy	15
HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B	14
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis	14
Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV	14
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known	14
Neurogastroenterology and motility disorders in patients with cirrhosis	14
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy	14
Predicting hepatic encephalopathy in patients with cirrhosis: A UK population–based study and validation of risk scores	14
Immune‐mediated liver injury following COVID‐19 vaccination: A systematic review	14
The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD	14
Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD	14
Ablation of high‐mobility group box‐1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling‐deficient mice	14
Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival	14
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study	14
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population	14
Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis	14
Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR	14
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus	14
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis	13
Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis	13
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD	13
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice	13
Financial burden in a US cohort of patients with HCC	13
Cytomegalovirus infection in patients with biliary atresia—further questions and possible solutions	13
Erratum: Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	13
A Quantitative Magnetic Resonance Cholangiopancreatography Metric of Intrahepatic Biliary Dilatation Severity Detects High‐Risk Primary Sclerosing Cholangitis	13
Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis	13
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index	13
A versatile method to profile hepatitis B virus DNA integration	13
Learn, adapt, act: A pragmatic approach for intervening on disparities in hepatocellular carcinoma outcomes	13
Baveno VII for HCC: Are we there yet?	13
Reply	13
Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID‐19 Pandemic: A National Cohort Study	13
An optimized peritonitis-induced ACLF model that reproduces the full spectrum of extrahepatic organ failures in mice	13
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system	13
Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study	13
Assessing the risk of surgery in patients with cirrhosis	13
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study	13
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents	13
HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores	13
Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study	12
A windfall year for HCC: The most impactful clinical papers in 2023	12
Heterologous adenovirus‐vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients	12
Problematic alcohol use and its impact on liver disease quality of life in a multicenter study of patients with cirrhosis	12
GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study	12
Ethanol disrupts hepatocellular lipophagy by altering Rab5-centric LD-lysosome trafficking	12
Erratum: Live-smart: A sequential, multiple assignment randomized trial to reduce falls in cirrhosis	12
Maternal Western diet is associated with distinct preclinical pediatric NAFLD phenotypes in juvenile nonhuman primate offspring	12
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis	12
Deletion of adipocyte prohibitin 1 exacerbates high‐fat diet‐induced steatosis but not liver inflammation and fibrosis	12
Alcohol‐Induced Liver Injury: Down‐regulation and Redistribution of Rab3D Results in Atypical Protein Trafficking	12
Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study	12
Role of mitogens in normal and pathological liver regeneration	12
HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection	12
Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH	12
The Integrated “Multiomics” Landscape at Peak Injury and Resolution From Alcohol‐Associated Liver Disease	12
A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance	12
A River From the Liver: Detecting Hepatocyte Genomic DNA in Urine	12
The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: A prospective study	12
LKB1 acts as a critical brake for the glucagon‐mediated fasting response	12
Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease	12
Loss of phospholipase Cγ1 suppresses hepatocellular carcinogenesis through blockade of STAT3‐mediated cancer development	12
Issue Information	12
Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis	12
Roles of RNA m6A modification in nonalcoholic fatty liver disease	12